Executive Summary 

• The Food and Drug Administration has authorized 26 nicotine pouch products. Hundreds more sell without clearance, so the legal market is a small fraction of the shelf. 

• For most of those unauthorized products, illegal means the FDA never finished reviewing them. It does not mean the agency examined them and judged them dangerous. 

• A dangerous product built to hook teenagers and a mild one the FDA simply has not reviewed are equally illegal, so the label fails to educate buyers on which products carry real risk. 

Introduction 

At U.S. gas stations, the nicotine pouch shelf runs dozens of brands deep, at every strength. The Food and Drug Administration (FDA) has cleared about two dozen of them, all at the lower-strength end. Almost everything else on that shelf is, under federal law, illegal to sell. The word suggests that the government examined these products and found them unsafe. For most of them, the government has not examined them at all. When the FDA did look closely, clearing ZYN, it found a product far less harmful than a cigarette. For most of the shelf that hard look never came, so a missing clearance marks an unfinished review, not a failed one. What follows explains why the legal list stays so short, and why the illegal pouches keep selling anyway. 

What a Pouch Is, and the Scale of the Market 

A nicotine pouch is a small, tobacco-free packet held between the lip and gum. Inside is nicotine, drawn from tobacco or made in a lab, mixed with flavoring, sweeteners, and plant fibers that give the pouch its shape. Nothing burns. Nothing gets spit out. And with no tobacco leaf, a pouch is not snus, nor one of the nicotine gums and lozenges the FDA regulates as medicines. The nicotine crosses into the blood through the lining of the mouth. Strength is printed on the can in milligrams, and that number sits at the center of the regulatory fight. 

The market has exploded. ZYN, the brand that leads it, shipped about 794 million cans in the U.S. in 2025, up from roughly 580 million the year before, a rise of about 37 percent in a single year. A product first sold in 2014 now moves hundreds of millions of units a year, and pouches have become the fastest-growing nicotine category in the United States. That boom pulled in hundreds of competing brands, most of them unauthorized. 

A Short Legal List in a Crowded Market 

Nicotine pouches count as tobacco products under federal law, so no company can sell them legally without a marketing order from the FDA, granted through the Premarket Tobacco Product Application (PMTA). The agency granted that order to 20 ZYN variants in January 2025, after years of review, along with six other products from Helix Innovations. That makes up the entire legal market. 

Hundreds of other pouches sell regardless, and they are all illegal in different ways. The FDA reviewed a small number and turned them down, a formal denial. A far larger number it never ruled on. Some companies have never applied. Others applied and are selling while they wait, because in May 2026 the FDA said it would not act against pouches whose applications are under review. These unreviewed products, the bulk of the shelf, carry no federal safety verdict at all. On the shelf, they all look the same. A shopper cannot tell a cleared product from a rejected one, or from one the agency has never examined, because they sell side by side at a similar price with no labels in store. 

The FDA’s own compliance materials had long held that a pending application is no license to sell. The 2026 guidance set that aside for pouches under review, so a product can be illegal under the statute and still sell in every state with the agency’s permission. 

Why So Few Products Clear the Bar 

Two forces keep the legal list short, and the gray market large: approval is expensive to win and ignoring it costs little. 

Approval is hard to achieve. A company must show the FDA that selling its product is “appropriate for the protection of public health.” In practice, that means proving it helps smokers switch without drawing in nonsmokers or teenagers, which takes years of studies and millions of dollars. A single application can cost several million dollars, sometimes tens of millions. Most small firms cannot afford that, so only the largest companies hold authorizations. 

The timing made it worse. These products are newer than the system that now governs them. The FDA’s authority over nicotine expanded in stages, and not until a 2022 law, effective that April, did it clearly cover every nicotine product regardless of where the nicotine came from. By then the pouch market was already large and growing fast. The law pulled an established market under federal review all at once; more applications than the agency could work through flooded in, and the backlog has not cleared. 

Ignoring approval is cheap and has a low risk. A company that never applies skips the studies, the manufacturing standards, and the application cost, and so far has faced little enforcement. Its product reaches shelves first and undercuts the authorized ones. Nothing forces it off the market, so it stays. 

Conclusion 

Most of what sells is illegal, but illegal here mostly means unreviewed, not unsafe. The FDA’s label sorts pouches by whose paperwork is done. Whether a product is dangerous never enters into it. It cannot tell a doctor or a parent which products to worry about. 

High-strength and kid-targeted pouches are the ones that send children to poison control, and they sit on the shelf next to mild products the FDA simply hasn’t gotten to, under the same “illegal” label. Any fix starts there: go after the products that do harm and clear the backlog, so the word “illegal” means something again.